BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Finck AV, Blanchard T, Roselle CP, Golinelli G, June CH. Engineered cellular immunotherapies in cancer and beyond. Nat Med 2022;28:678-89. [PMID: 35440724 DOI: 10.1038/s41591-022-01765-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Irvine DJ, Maus MV, Mooney DJ, Wong WW. The future of engineered immune cell therapies. Science 2022;378:853-858. [DOI: 10.1126/science.abq6990] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Li J, Huang F, Jiang Y, Zhao J, Wan J, Hao S. A novel costimulatory molecule gene-modified leukemia cell-derived exosome-targeted CD4+ T cell vaccine efficiently enhances anti-leukemia immunity. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1043484] [Reference Citation Analysis]
3 Yu H, Wu M, Chen S, Song M, Yue Y. Biomimetic nanoparticles for tumor immunotherapy. Front Bioeng Biotechnol 2022;10. [DOI: 10.3389/fbioe.2022.989881] [Reference Citation Analysis]
4 Tsokos GC. Engineered T cells to treat lupus arrive on the scene. Nature 2022. [DOI: 10.1038/d41586-022-03563-1] [Reference Citation Analysis]
5 Hazane Leroyer E, Ziegler C, Moulin C, Campidelli A, Jacquet C, Rubio MT, Feugier P, Pagliuca S. Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma. JCM 2022;11:6574. [DOI: 10.3390/jcm11216574] [Reference Citation Analysis]
6 Castelli S, Young RM, June CH. Off-the-shelf CAR T cells to treat cancer. Cell Res 2022. [DOI: 10.1038/s41422-022-00745-4] [Reference Citation Analysis]
7 Zagorulya M, Spranger S. Once upon a prime: DCs shape cancer immunity. Trends in Cancer 2022. [DOI: 10.1016/j.trecan.2022.10.006] [Reference Citation Analysis]
8 Baker DJ, June CH. CAR T therapy extends its reach to autoimmune diseases. Cell 2022;185:4471-4473. [DOI: 10.1016/j.cell.2022.10.026] [Reference Citation Analysis]
9 Wang J, Du L, Chen X. Adenosine signaling: Optimal target for gastric cancer immunotherapy. Front Immunol 2022;13:1027838. [DOI: 10.3389/fimmu.2022.1027838] [Reference Citation Analysis]
10 Toffalori C, Vago L. Bispecifics need a mindful pause. Blood 2022;140:1056-8. [PMID: 36074532 DOI: 10.1182/blood.2022017726] [Reference Citation Analysis]
11 Yuan ZG, Zeng TM, Tao CJ. Current and emerging immunotherapeutic approaches for biliary tract cancers. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00201-6. [PMID: 36115807 DOI: 10.1016/j.hbpd.2022.08.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Xue JN, Wang YY, Wang YC, Zhang N, Zhang LH, Lu ZH, Zhao LJ, Zhao HT. Novel cellular therapies for hepatobiliary malignancies. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00200-4. [PMID: 36100543 DOI: 10.1016/j.hbpd.2022.08.014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Fang T, Li C, Liang A, Zhang H, Zhang F, Zhang X, Yang Y, Li F. Probing cell membrane integrity using a histone-targeting protein nanocage displaying precisely positioned fluorophores. Nano Res . [DOI: 10.1007/s12274-022-4785-5] [Reference Citation Analysis]
14 Lau D, Corrie PG, Gallagher FA. MRI techniques for immunotherapy monitoring. J Immunother Cancer 2022;10:e004708. [PMID: 36122963 DOI: 10.1136/jitc-2022-004708] [Reference Citation Analysis]
15 Liu S, Nguyen K, Park D, Wong N, Wang A, Zhou Y, Cui Y. Harnessing natural killer cells to develop next‐generation cellular immunotherapy. Chronic Diseases and Translational Medicine. [DOI: 10.1002/cdt3.40] [Reference Citation Analysis]
16 Shen Y, Yu L, Xu X, Yu S, Yu Z. Neoantigen vaccine and neoantigen‐specific cell adoptive transfer therapy in solid tumors: Challenges and future directions. Cancer Innovation 2022;1:168-182. [DOI: 10.1002/cai2.26] [Reference Citation Analysis]